- Analyses highlight long-term efficacy and safety
results, including real-world data, from studies of
SKYRIZI® (risankizumab) in moderate to severe psoriasis
and active psoriatic arthritis
- Presentations include data from the largest-of-its-kind
study that demonstrates the real-world burden of atopic
dermatitis
- Breadth of data underscores AbbVie's commitment to advancing
research in dermatology for people living with immune-mediated skin
diseases such as psoriasis, psoriatic arthritis, atopic dermatitis
and vitiligo
NORTH
CHICAGO, Ill., Aug. 29,
2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today
announced it will present 23 abstracts at the 31st
European Academy of Dermatology and Venereology (EADV) Congress,
including a late-breaking oral presentation on long-term efficacy
and safety data of SKYRIZI® (risankizumab) in psoriatic
arthritis and real-world data from MEASURE-AD to assess the
multidimensional burden of atopic dermatitis. This research
demonstrates AbbVie's commitment to deepening the understanding of
immune-mediated skin diseases by investing in studies of
difficult-to-treat patient populations, certain disease areas with
few existing treatment options as well as real-world patient
experience. The hybrid congress will take place from September 7-10, in Milan, as well as virtually.
"Our leadership in dermatology runs deep – from developing
innovative technologies to studying lesser-understood diseases
where few to no treatment options currently exist," said Chiedzo
Mpofu, MBChB, Ph.D., vice president, Global Medical Affairs,
Immunology, AbbVie. "At this year's EADV Congress, we're presenting
a range of data, including real-world, patient-centered research
that will help elevate the community's understanding of the
long-term impact of our treatments and the potential to support
patients with difficult-to-treat diseases."
Key data to be presented include:
- Late-breaking oral presentation of new data from the ongoing
Phase 3 active psoriatic arthritis clinical trials, KEEPsAKE 1 and
KEEPsAKE 2, evaluating long-term efficacy and safety, up to 100
weeks, in patients treated with SKYRIZI (risankizumab)
- Analyses from MEASURE-AD, a cross-sectional, 28-country, burden
of disease study aimed to characterize global treatment patterns,
healthcare resource utilization and costs, and the clinical and
economic burden of moderate to severe atopic dermatitis
- Results from VALUE, a 13-month interim analysis from a
long-term, prospective observational study that has enrolled 2,700
patients from 21 countries, evaluating real-world efficacy,
durability of response and time to first treatment change for
moderate to severe psoriasis patients treated with SKYRIZI
(risankizumab) compared to other commonly used treatments
- Results from aIMM, a Phase 3b,
multicenter, interventional, open-label, single-arm study analyzing
clinical efficacy, safety and quality-of-life outcomes after 16
weeks of treatment with SKYRIZI (risankizumab) in psoriasis
patients who previously achieved suboptimal responses to one of two
IL-17 inhibitors, either secukinumab or ixekizumab
- Interim analysis of the nearly 5-year (256 weeks) LIMMitless
open-label extension study evaluating long-term efficacy and safety
data with continuous SKYRIZI (risankizumab) treatment in patients
with moderate to severe plaque psoriasis
- Two real-world insurance claims database analyses examining
economic and comorbidity impacts on patients with vitiligo
AbbVie abstracts at the EADV Congress include:
Abstract Title
|
Session Details (All Times
CEST)
|
Risankizumab / Psoriasis
|
|
Efficacy of Risankizumab in Psoriasis Patients
Participating in the VALUE
Multi-Country Post-Marking Observational
Study
|
Poster
Session
P1538
Wednesday, Sept
7
7:00 a.m.
|
Efficacy and Safety of Risankizumab in Psoriasis
Patients Who Had a
Suboptimal Response to Secukinumab or
Ixekizumab
|
Poster
Session
P1537
Wednesday, Sept
7
7:00 a.m.
|
Long-Term Safety and Efficacy of Risankizumab for the
Treatment of
Moderate to Severe Plaque Psoriasis: A 4.5-year Interim Analysis of
the
LIMMitless Open-Label Extension Trial
|
Poster
Session
P1603
Wednesday, Sept
7
7:00 a.m.
|
Efficacy and Safety of Long-Term Risankizumab
Treatment for Nail, Scalp,
and Palmoplantar Psoriasis: A 4.5-Year Interim Analysis from the
LIMMitless
Open-Label Extension Trial
|
Poster
Session
P1551
Wednesday, Sept
7
7:00 a.m.
|
Efficacy of Risankizumab for Moderate to Severe
Plaque Psoriasis Through
256 Weeks: Subgroup Analysis by Baseline Demographics and
Disease
Characteristics from the LIMMitless Trial
|
Poster
Session
P1553
Wednesday, Sept
7
7:00 a.m.
|
Real-World Switching and Discontinuation Patterns for
Interleukin-Inhibitor
Treatments in Patients with Moderate to Severe Psoriasis in
Japan
|
Poster
Session
P1558
Wednesday, Sept
7
7:00 a.m.
|
Dose Escalation of Biologic Treatment in Patients
with Moderate to Severe
Psoriasis in Japan
|
Poster
Session
P1606
Wednesday, Sept
7
7:00 a.m.
|
Real-World Achievement of Absolute Psoriasis Area and
Severity Index
Thresholds with Risankizumab in Patients with Moderate to Severe
Psoriasis
From the CorEvitas Psoriasis Registry
|
Poster
Session
P1557
Wednesday, Sept
7
7:00 a.m.
|
Risankizumab / Psoriatic
Arthritis
|
|
Efficacy and Safety of Risankizumab for Active
Psoriatic Arthritis: 100-Week
Results from the KEEPsAKE 1 and KEEPsAKE 2
Trials
|
Late-breaking News
Session
D3T01.1
Saturday, Sept 10
9:15 - 9:30 a.m.
|
Durability of Clinically Meaningful Improvements in
Patient-Reported
Outcomes and Work Productivity Among Patients with Psoriatic
Arthritis
Receiving Risankizumab: Results from KEEPsAKE 1 and
2
|
Poster
Session
P1429
Wednesday, Sept
7
7:00 a.m.
|
Impact of Risankizumab on Enthesitis and Dactylitis:
Integrated Analysis of the
Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2
Trials
|
Poster
Session
P1605
Wednesday, Sept
7
7:00 a.m.
|
Risankizumab (RZB) Demonstrates Long-term Efficacy
Across Subgroups in
Patients with Active Psoriatic Arthritis (PsA): A Post Hoc,
Integrated Analysis
from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2)
Studies
|
Poster
Session
P1545
Wednesday, Sept
7
7:00 a.m.
|
Risankizumab Long-Term Safety in Patients with
Psoriatic Disease: Integrated
Analyses of Data from Psoriasis and Psoriatic Arthritis Clinical
Trials
|
Poster
Session
P1607
Wednesday, Sept
7
7:00 a.m.
|
Efficacy Analysis in Patients with Active Psoriatic
Arthritis and Significant
Involvement of Skin Manifestations
|
Poster
Session
P1568
Wednesday, Sept
7
7:00 a.m.
|
Upadacitinib / Atopic
Dermatitis
|
|
Efficacy of Upadacitinib vs Dupilumab for Moderate to
Severe Atopic
Dermatitis: Analysis of Time Spent in Response State from the Heads
Up Study
|
Poster
Session
P0256
Wednesday, Sept
7
7:00 a.m.
|
Effect of Upadacitinib on Cutaneous Transcriptomic
and Systemic Proteomic
Dysregulation in Patients with Moderate to Severe Atopic
Dermatitis
|
Free Communications in
Atopic Dermatitis Session
FC03.02
Thursday, Sept
8
14:25 - 14:35
p.m.
|
Efficacy and Safety of Upadacitinib with Topical
Corticosteroids for the
Treatment of Atopic Dermatitis in Japan: 2-Year Interim Results
from the
Phase 3 Rising Up Study
|
Free Communications in
Atopic Dermatitis Session
FC03.05
Thursday, Sept
8
14:55 - 15:05
p.m.
|
Disease State Abstracts:
Psoriasis
|
|
Epidemiologic Survey on Prevalence of Genital
Psoriasis and Its Impact on
Patients' Sexual Life in Routine Care
|
Poster
Session
P1564
Wednesday, Sept
7
7:00 a.m.
|
Disease State Abstracts: Atopic
Dermatitis
|
|
Real-World Burden in Patients with Atopic Dermatitis
Who Are Candidates for
Systemic Therapy and Currently Receiving No Systemic Therapy,
No
Treatment, Topical Therapy Only, or Systemic Therapy: Results from
a Real-
World Multicountry Study
|
Free Communications in
Atopic Dermatitis Session
FC02.02
Thursday, Sept
8
10:25 - 10:35
a.m.
|
Associations Between Patient-Reported Outcomes and
Disease Severity
Measures with Disease Burden in Atopic Dermatitis: Results from a
Real-
World Multicountry Study
|
Poster
Session
P0286
Wednesday, Sept
7
7:00 a.m.
|
Comparative Risk of Venous Thromboembolism (VTE)
Among Patients with
Atopic Dermatitis (AD) or Other Immune-Mediated Diseases: A Cohort
Study
Using United States Claims Data
|
Poster
Session
P0201
Wednesday, Sept
7
7:00 a.m.
|
Disease State Abstracts:
Vitiligo
|
|
Economic Burden Among Patients with Vitiligo in the
US: A Retrospective
Database Claims Study
|
Poster
Session
P1389
Wednesday, Sept
7
7:00 a.m.
|
Comorbidity Burden Among Patients with Vitiligo in
the US: A Large-Scale
Retrospective Claims Database Analysis
|
Poster
Session
P1378
Wednesday, Sept
7
7:00 a.m.
|
The full EADV scientific program is available here.
SKYRIZI is part of a collaboration between Boehringer Ingelheim
and AbbVie, with AbbVie leading the development and
commercialization of SKYRIZI globally.
About SKYRIZI® (risankizumab)
SKYRIZI is an
interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by
binding to its p19 subunit. IL-23, a cytokine involved in
inflammatory processes, is thought to be linked to a number of
chronic immune-mediated diseases.1,2 Phase 3 trials of
SKYRIZI in psoriasis, psoriatic arthritis, Crohn's disease and
ulcerative colitis are ongoing.3-5
US Indications and Important Safety Information about
SKYRIZI® (risankizumab-rzaa)2
SKYRIZI is a prescription medicine used to treat adults
with:
- moderate to severe plaque psoriasis who may benefit from taking
injections or pills (systemic therapy) or treatment using
ultraviolet or UV light (phototherapy).
- active psoriatic arthritis (PsA).
- moderate to severe Crohn's disease.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about
SKYRIZI® (risankizumab-rzaa)?
SKYRIZI is a prescription medication that may cause serious
side effects, including:
Serious Allergic Reactions:
Stop using SKYRIZI and get emergency medical help right away if you
get any of the following symptoms of a serious allergic
reaction:
- Fainting, dizziness, feeling lightheaded (low blood
pressure)
- Swelling of your face, eyelids, lips, mouth, tongue, or
throat
- Trouble breathing or throat tightness
- Chest tightness
- Skin rash, hives
- Itching
Infections:
SKYRIZI may lower the ability of your immune system to fight
infections and may increase your risk of infections. Your
healthcare provider should check you for infections and
tuberculosis (TB) before starting treatment with SKYRIZI and may
treat you for TB before you begin treatment with SKYRIZI if you
have a history of TB or have active TB. Your healthcare provider
should watch you closely for signs and symptoms of TB during and
after treatment with SKYRIZI.
- Tell your healthcare provider right away if you have an
infection or have symptoms of an infection, including:
-
- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from
your psoriasis
- diarrhea or stomach pain
- shortness of breath
- blood in your mucus (phlegm)
- burning when you urinate or urinating more often than
normal
Do not use SKYRIZI if you are allergic to
risankizumab-rzaa or any of the ingredients in SKYRIZI.
Before using SKYRIZI, tell your healthcare provider about all
of your medical conditions, including if you:
- have any of the conditions or symptoms listed in the section
"What is the most important information I should know about
SKYRIZI?"
- have an infection that does not go away or that keeps coming
back.
- have TB or have been in close contact with someone with
TB.
- have recently received or are scheduled to receive an
immunization (vaccine). Medicines that interact with the immune
system may increase your risk of getting an infection after
receiving live vaccines. You should avoid receiving live vaccines
right before, during, or right after treatment with SKYRIZI. Tell
your healthcare provider that you are taking SKYRIZI before
receiving a vaccine.
- are pregnant or plan to become pregnant. It is not known if
SKYRIZI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if
SKYRIZI passes into your breast milk.
Tell your healthcare provider about all the medicines you take,
including prescription and over-the-counter medicines, vitamins,
and herbal supplements.
What are the possible side effects of SKYRIZI?
SKYRIZI may cause serious side effects. See "What is the most
important information I should know about SKYRIZI?"
Liver problems in people with Crohn's disease: A
person with Crohn's disease who received SKYRIZI by intravenous
infusion developed changes in liver blood tests with a rash that
led to hospitalization. Your doctor will do blood tests to check
your liver before, during, and up to 12 weeks of treatment and may
stop treatment with SKYRIZI if you develop liver problems. Tell
your doctor right away if you notice any of the following symptoms:
unexplained rash, nausea, vomiting, stomach (abdominal) pain,
tiredness (fatigue), loss of appetite, yellowing of the skin and
eyes (jaundice) and dark urine.
The most common side effects of SKYRIZI in people treated for
Crohn's Disease include upper respiratory infections, injection
site reactions, fever, headache, stomach (abdominal) pain, back
pain, joint pain, and low red blood cells (anemia).
The most common side effects of SKYRIZI in people treated for
plaque psoriasis and psoriatic arthritis include upper respiratory
infections, feeling tired, fungal skin infections, headache, and
injection site reactions.
These are not all the possible side effects of SKYRIZI. Call
your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use
it.
SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a
600 mg/10 mL intravenous infusion, and a 360 mg/2.4 mL single-dose
prefilled cartridge with on-body injector.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help. Visit AbbVie.com/myAbbVieAssist to learn
more.
Please click here for Full Prescribing Information and
Medication Guide for SKYRIZI.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a
selective JAK inhibitor that is being studied in several
immune-mediated inflammatory diseases.6 Based on
enzymatic and cellular assays, RINVOQ demonstrated greater
inhibitory potency for JAK-1 vs JAK-2, JAK-3 and TYK-2.6
The relevance of inhibition of specific JAK enzymes to therapeutic
effectiveness and safety is not currently known. Phase 3 trials of
RINVOQ in atopic dermatitis, axial spondylarthritis, Crohn's
disease, giant cell arteritis, psoriatic arthritis, rheumatoid
arthritis, Takayasu arteritis and ulcerative colitis are
ongoing.5,7-15
US Indications and Important Safety Information about
RINVOQ® (upadacitinib)6
USES
RINVOQ is a prescription medicine used to
treat:
- Adults with moderate to severe rheumatoid arthritis when
1 or more medicines called tumor necrosis factor (TNF) blockers
have been used, and did not work well or could not be
tolerated.
- Adults with active psoriatic arthritis when 1 or more
medicines called TNF blockers have been used, and did not work well
or could not be tolerated.
- Adults with moderate to severe ulcerative colitis when 1
or more medicines called TNF blockers have been used, and did not
work well or could not be tolerated.
- Adults with active ankylosing spondylitis when 1 or more
medicines called TNF blockers have been used, and did not work well
or could not be tolerated.
It is not known if RINVOQ is safe and effective in children with
juvenile idiopathic arthritis, psoriatic arthritis, ulcerative
colitis, or ankylosing spondylitis.
- Adults and children 12 years of age and older with moderate
to severe eczema (atopic dermatitis) that did not respond to
previous treatment and their eczema is not well controlled with
other pills or injections, including biologic medicines, or the use
of other pills or injections is not recommended.
RINVOQ is safe and effective in children 12 years of age and
older weighing at least 88 pounds (40 kg) with atopic
dermatitis.
It is not known if RINVOQ is safe and effective in children
under 12 years of age with atopic dermatitis.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about
RINVOQ?
RINVOQ may cause serious side effects, including:
- Serious infections. RINVOQ can lower your ability to
fight infections. Serious infections have happened while taking
RINVOQ, including tuberculosis (TB) and infections caused by
bacteria, fungi, or viruses that can spread throughout the body.
Some people have died from these infections. Your healthcare
provider (HCP) should test you for TB before starting RINVOQ and
check you closely for signs and symptoms of TB during treatment
with RINVOQ. You should not start taking RINVOQ if you have any
kind of infection unless your HCP tells you it is okay. If you get
a serious infection, your HCP may stop your treatment until your
infection is controlled. You may be at higher risk of developing
shingles (herpes zoster).
- Increased risk of death in people 50 years and older who
have at least 1 heart disease (cardiovascular) risk
factor.
- Cancer and immune system problems. RINVOQ may increase
your risk of certain cancers. Lymphoma and other cancers, including
skin cancers, can happen. Current or past smokers are at higher
risk of certain cancers, including lymphoma and lung cancer. Follow
your HCP's advice about having your skin checked for skin cancer
during treatment with RINVOQ. Limit the amount of time you spend in
sunlight. Wear protective clothing when you are in the sun and use
sunscreen.
- Increased risk of major cardiovascular (CV) events, such as
heart attack, stroke, or death, in people 50 years and older who
have at least 1 heart disease (CV) risk factor, especially if you
are a current or past smoker.
- Blood clots. Blood clots in the veins of the legs
or lungs and arteries can happen with RINVOQ. This may be
life-threatening and cause death. Blood clots in the veins of the
legs and lungs have happened more often in people who are 50 years
and older and with at least 1 heart disease (CV) risk factor.
- Allergic reactions. Symptoms such as rash (hives),
trouble breathing, feeling faint or dizzy, or swelling of your
lips, tongue, or throat, that may mean you are having an allergic
reaction have been seen in people taking RINVOQ. Some of these
reactions were serious. If any of these symptoms occur during
treatment with RINVOQ, stop taking RINVOQ and get emergency medical
help right away.
- Tears in the stomach or intestines and changes in certain
laboratory tests. Your HCP should do blood tests before you
start taking RINVOQ and while you take it. Your HCP may stop your
RINVOQ treatment for a period of time if needed because of changes
in these blood test results.
Do not take RINVOQ if:
- You are allergic to upadacitinib or any of the ingredients
in RINVOQ.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
- Are being treated for an infection, have an infection that
won't go away or keeps coming back, or have symptoms of an
infection, such as:
- Fever, sweating, or
chills
- Shortness of
breath
- Warm, red, or
painful skin or sores on your body
|
- Muscle
aches
- Feeling
tired
- Blood in
phlegm
- Diarrhea or stomach
pain
|
- Cough
- Weight
loss
- Burning when
urinating or urinating more often than normal
|
- Have TB or have been in close contact with someone with
TB.
- Are a current or past smoker.
- Have had a heart attack, other heart problems, or stroke.
- Have or have had any type of cancer, hepatitis B or C, shingles
(herpes zoster), blood clots in the veins of your legs or lungs,
diverticulitis (inflammation in parts of the large intestine), or
ulcers in your stomach or intestines.
- Have other medical conditions, including liver problems, low
blood cell counts, diabetes, chronic lung disease, HIV, or a weak
immune system.
- Live, have lived, or have traveled to parts of the country,
such as the Ohio and Mississippi
River valleys and the Southwest, that increase your risk of getting
certain kinds of fungal infections. If you are unsure if you've
been to these types of areas, ask your HCP.
- Have recently received or are scheduled to receive a vaccine.
People who take RINVOQ should not receive live vaccines.
- Are pregnant or plan to become pregnant. Based on animal
studies, RINVOQ may harm your unborn baby. Your HCP will check
whether or not you are pregnant before you start RINVOQ. You should
use effective birth control (contraception) to avoid becoming
pregnant during treatment with RINVOQ and for 4 weeks after your
last dose.
- Are breastfeeding or plan to breastfeed. RINVOQ may pass into
your breast milk. Do not breastfeed during treatment with RINVOQ
and for 6 days after your last dose.
Tell your HCP about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal
supplements. RINVOQ and other medicines may affect each other,
causing side effects.
Especially tell your HCP if you take:
- Medicines for fungal or bacterial infections
- Rifampicin or phenytoin
- Medicines that affect your immune system
If you are not sure if you are taking any of these medicines,
ask your HCP or pharmacist.
What should I do or tell my HCP AFTER starting
RINVOQ?
- Tell your HCP right away if you have any symptoms of an
infection. RINVOQ can make you more likely to get infections or
make any infections you have worse.
- Get emergency help right away if you have any symptoms of a
heart attack or stroke while taking RINVOQ, including:
-
- Discomfort in the center of your chest that lasts for more than
a few minutes or that goes away and comes back
- Severe tightness, pain, pressure, or heaviness in your chest,
throat, neck, or jaw
- Pain or discomfort in your arms, back, neck, jaw, or
stomach
- Shortness of breath with or without chest discomfort
- Breaking out in a cold sweat
- Nausea or vomiting
- Feeling lightheaded
- Weakness in one part or on one side of your body
- Slurred speech
- Tell your HCP right away if you have any signs or symptoms of
blood clots during treatment with RINVOQ, including:
- Swelling
- Pain or tenderness
in one or both legs
|
- Sudden unexplained
chest or upper back pain
- Shortness of breath
or difficulty breathing
|
- Tell your HCP right away if you have a fever or stomach-area
pain that does not go away, and a change in your bowel habits.
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections
(common cold, sinus infections), shingles (herpes zoster), herpes
simplex virus infections (including cold sores), bronchitis,
nausea, cough, fever, acne, headache, increased blood levels of
creatine phosphokinase, allergic reactions, inflammation of hair
follicles, stomach-area (abdominal) pain, increased weight, flu,
tiredness, lower number of certain types of white blood cells
(neutropenia, lymphopenia), muscle pain, flu-like illness, rash,
increased blood cholesterol levels, and increased liver enzyme
levels.
A separation or tear to the lining of the back part of the eye
(retinal detachment) has happened in people with atopic dermatitis
treated with RINVOQ. Call your HCP right away if you have any
sudden changes in your vision during treatment with RINVOQ.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ?
RINVOQ is taken once a day with or without food. Do not split,
crush, or chew the tablet. Take RINVOQ exactly as your HCP tells
you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg
extended-release tablets.
This is the most important information to know about RINVOQ.
For more information, talk to your HCP.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help. Visit AbbVie.com/myAbbVieAssist to learn
more.
Please click here for the Full Prescribing Information and
Medication Guide.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
About AbbVie in Dermatology
For more than a
decade, AbbVie has worked to uncover new solutions and improve care
for people with serious skin diseases, including psoriasis,
psoriatic arthritis, hidradenitis suppurativa and atopic
dermatitis. With a broad clinical trial program, we continue to
actively research and adapt to the evolving needs of the
dermatology community and advance our pipeline to help people
achieve their treatment goals and live beyond their skin disease.
For more information on AbbVie in dermatology,
visit https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/dermatology.html.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines that solve serious health issues today
and address the medical challenges of tomorrow. We strive to have a
remarkable impact on people's lives across several key therapeutic
areas: immunology, oncology, neuroscience, eye care, virology,
women's health and gastroenterology, in addition to products and
services across our Allergan Aesthetics portfolio. For more
information about AbbVie, please visit us at www.abbvie.com. Follow
@abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
Some statements in this
news release are, or may be considered, forward-looking statements
for purposes of the Private Securities Litigation Reform Act of
1995. The words "believe," "expect," "anticipate," "project" and
similar expressions, among others, generally identify
forward-looking statements. AbbVie cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Such risks and
uncertainties include, but are not limited to, failure to realize
the expected benefits from AbbVie's acquisition of Allergan plc
("Allergan"), failure to promptly and effectively integrate
Allergan's businesses, competition from other products, challenges
to intellectual property, difficulties inherent in the research and
development process, adverse litigation or government action,
changes to laws and regulations applicable to our industry and the
impact of public health outbreaks, epidemics or pandemics, such as
COVID-19. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2021 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
References:
- Duvallet E., Sererano L., Assier E., et al. Interleukin-23: a
key cytokine in inflammatory diseases. Ann Med. 2011. Nov
43(7):503-11.
- SKYRIZI [package insert]. North
Chicago, IL: AbbVie Inc.; 2022.
- A Study of the Efficacy and Safety of Risankizumab in
Participants with Crohn's Disease. ClinicalTrials.gov. 2021.
Available at: https://clinicaltrials.gov/ct2/show/NCT03105102.
Accessed August 5, 2022.
- A Multicenter, Randomized, Double-Blind, Placebo Controlled
Induction Study to Evaluate the Efficacy and Safety of Risankizumab
in Participants with Moderately to Severely Active Ulcerative
Colitis. ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/record/NCT03398148. Accessed on
August 5, 2022.
- Pipeline – Our Science | AbbVie. AbbVie. 2021. Available at:
https://www.abbvie.com/our-science/pipeline.html. Accessed on
August 5, 2022.
- Abbvie, Ltd. RINVOQ [package insert]. North Chicago, IL: AbbVie Inc.; 2022.
- Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction
and maintenance therapy for moderately to severely active
ulcerative colitis: results from three phase 3, multicentre,
double-blind, randomised trials. The Lancet.
2022;399(10341):2113-2128. doi:10.1016/S0140-6736(22)00581-5
- Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for
psoriatic arthritis refractory to biologics: SELECT-PsA 2. Annals
of the Rheumatic Diseases. 2021;80(3):312-320.
doi:10.1136/annrheumdis-2020-218870
- Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily
upadacitinib versus placebo in adolescents and adults with
moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up
2): results from two replicate double-blind, randomised controlled
phase 3 trials. The Lancet. 2021;397(10290):2151-2168.
doi:10.1016/S0140-6736(21)00588-2
- van der Heijde D, Song IH, Pangan AL, et al. Efficacy and
safety of upadacitinib in patients with active ankylosing
spondylitis (SELECT-AXIS 1): a multicentre, randomised,
double-blind, placebo-controlled, phase 2/3 trial. Lancet.
2019;394(10214):2108-2117. doi:10.1016/S0140-6736(19)32534-6.
- A Study to Evaluate the Long-Term Safety and Efficacy of
Upadacitinib (ABT-494) in Participants with Ulcerative Colitis
(UC). clinicaltrials.gov; 2022. Available at:
https://clinicaltrials.gov/ct2/show/NCT03006068. Accessed on
August 5, 2022.
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in
Subjects with Takayasu Arteritis (TAK) (SELECT-TAK).
clinicaltrials.gov; 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT04161898. Accessed on
August 5, 2022.
- A Study to Evaluate Efficacy and Safety of Upadacitinib in
Adult Participants with Axial Spondyloarthritis.
clinicaltrials.gov; 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT04169373. Accessed on
August 5, 2022.
- A Study to Evaluate the Safety and Efficacy of Upadacitinib in
Participants with Giant Cell Arteritis. clinicaltrials.gov; 2022.
August 5, 2022.
https://clinicaltrials.gov/ct2/show/NCT03725202.
- A Maintenance and Long-Term Extension Study of the Efficacy and
Safety of Upadacitinib (ABT-494) in Participants with Crohn's
Disease Who Completed the Studies M14-431 or M14-433.
clinicaltrials.gov; 2022. August 5,
2022. https://clinicaltrials.gov/ct2/show/NCT03345823.
View original
content:https://www.prnewswire.com/news-releases/abbvie-showcases-new-analyses-and-real-world-data-across-multiple-immune-mediated-skin-diseases-at-the-european-academy-of-dermatology-and-venereology-eadv-2022-congress-301613527.html
SOURCE AbbVie